Fierce JPM Week 2025

With some of the industry’s top drugs moving toward patent cliffs later this decade, Big Pharma dealmakers have remained active despite economic uncertainties. The 2024 buyouts of Catalent, Alpine Immune Sciences and CymaBay Therapeutics—among others—showed that drugmakers were willing to strike deals for the right assets at the right prices. As the industry navigates the Inflation Reduction Act and other factors, biopharma leaders and venture capitalists on this panel will share their expectations for the year ahead.

As clinical trials expand across borders, sponsors face unique challenges that can slow progress and increase complexity. This panel will dive into the key hurdles holding sponsors back, from navigating varying regulatory requirements to overcoming cultural and language barriers. Industry experts will explore strategies to streamline regulatory approvals, improve trial efficiency across diverse regions, and leverage cultural insights to enhance patient recruitment and retention. Join us for a deep dive into the opportunities and solutions driving the future of international clinical trials.

As AI and machine learning continue to reshape biotech, medtech, and pharma, this panel will explore the latest trends, challenges, and opportunities for AI-driven advancements across these sectors. Experts will take an in-depth look at how AI is streamlining processes—from drug discovery to medical device development—and share real-world examples of its impact on patient care.

ADCs, bispecifics and radiopharmaceuticals are making waves in oncology treatment. Practice-changing clinical data have spurred major investments and deals. At the same time, much-touted cell therapies have run into real-world issues such as capacity and infrastructure limitations. During this panel, we will explore what’s next for these trends as the industry continues its efforts to advance patient care.

The biotech market made a comeback in 2024, recovering from a slump a year earlier. What will the IPO window look like in 2025? During this panel discussion, we will examine the performance of companies that went public in the second half of 2024 and how their success or challenges are impacting other startups’ decisions on whether to go public themselves

As healthcare embraces a more connected future, the need for real-time, global data access has become vital to bridging gaps in patient care and streamlining drug development. This panel delves into the challenges and opportunities in democratizing healthcare data, with a focus on integrated solutions and strategies that address data fragmentation and enable swift access to diverse patient and provider demographics. Join us to discover how democratizing healthcare data will shape the future of global patient care and catalyze advancements in the biopharma industry.

With advancements in platform technologies and automation, the cell and gene therapy space is poised for changes. During this panel discussion, industry leaders will explore challenges and share insights on navigating regulatory hurdles, optimizing manufacturing and leveraging emerging technologies to address broader disease states.